These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16359163)

  • 1. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
    Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
    Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
    J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
    Wiseman RL; Green NS; Kelly JW
    Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
    Sekijima Y; Dendle MA; Kelly JW
    Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
    Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
    J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
    Julius RL; Hawthorne MF
    Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
    Hammarström P; Wiseman RL; Powers ET; Kelly JW
    Science; 2003 Jan; 299(5607):713-6. PubMed ID: 12560553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
    Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
    J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
    Tojo K; Sekijima Y; Kelly JW; Ikeda S
    Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
    Green NS; Foss TR; Kelly JW
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
    Johnson SM; Petrassi HM; Palaninathan SK; Mohamedmohaideen NN; Purkey HE; Nichols C; Chiang KP; Walkup T; Sacchettini JC; Sharpless KB; Kelly JW
    J Med Chem; 2005 Mar; 48(5):1576-87. PubMed ID: 15743199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding.
    Miyata M; Sato T; Mizuguchi M; Nakamura T; Ikemizu S; Nabeshima Y; Susuki S; Suwa Y; Morioka H; Ando Y; Suico MA; Shuto T; Koga T; Yamagata Y; Kai H
    Biochemistry; 2010 Jan; 49(1):114-23. PubMed ID: 19950966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
    Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
    J Mol Biol; 2001 Mar; 306(4):733-44. PubMed ID: 11243784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
    Palaninathan SK
    Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
    Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
    Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
    Connelly S; Choi S; Johnson SM; Kelly JW; Wilson IA
    Curr Opin Struct Biol; 2010 Feb; 20(1):54-62. PubMed ID: 20133122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
    Sekijima Y; Kelly JW; Ikeda S
    Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.